Mass Azithromycin Administration in Malian Infants Shows No Mortality Benefit: A Large-Scale Randomized Trial

Highlight

• Mass administration of azithromycin to infants aged 1 to 11 months in Mali did not reduce mortality compared to placebo.
• The trial randomized 1151 villages to placebo, twice-yearly, or quarterly azithromycin administration, enrolling over 149,000 infants.
• Mortality rates were similar across the three groups with no statistically significant differences.
• Adverse event rates were low and comparable among groups, supporting safety but not efficacy in mortality reduction.

Study Background